scholarly journals HBV-DNA, HBeAg/anti-HBe serological status in hepatitis B chronic individuals from central Italy

1990 ◽  
Vol 104 (3) ◽  
pp. 511-518 ◽  
Author(s):  
M. Rapicetta ◽  
V. Di Nardo ◽  
C. Rozera ◽  
G. Marinucci ◽  
D. Francisci ◽  
...  
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Central Italy ◽  
Hbv Dna ◽  
Hbsag Carrier ◽  
Chronic Patients ◽  
Asymptomatic Carriers ◽  
Serological Status ◽  
Histological Activity ◽  
Normal Alt

SUMMARYA population of 488 HBsAg carrier individuals, from central Italy, classified on the basis of biochemical, clinical and histological parameters, was analysed for the presence of HBV-DNA in serum and its relationship with HBeAg/anti-HBe markers. The prevalence of HBV-DNA was 32·8% in chronic patients with biopsy-proven liver disease, and 20 and 4·3% respectively in asymptomatic carriers with and without altered ALT levels. The values in chronic patients were correlated with the histological activity.Concordance of HBV-DNA presence and HBeAg positivity was observed in only 61·4% of cases. However HBV-DNA prevalence in sera of anti-HBe positive individuals was very low in asymptomatic carriers with normal ALT levels (2·5%). Higher values were observed in anti-HBe positive chronic patients (15·8%) and in carriers occasionally found with changes in ALT without any other clinical sign of illness (16·7%). These data would indicate that HBV-DNA is the serological marker which is most closely related to liver disease.

scholarly journals Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Magdalena Świderska ◽  
Jerzy Jaroszewicz ◽  
Anna Parfieniuk-Kowerda ◽  
Magdalena Rogalska-Płońska ◽  
Agnieszka Stawicka ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Disease Activity ◽  
Chronic Hepatitis B ◽  
Hbv Infection ◽  
Cytokeratin 18 ◽  
Advanced Stages ◽  
Histological Activity ◽  
Normal Alt ◽  
New Biomarkers

Chronic hepatitis B has highly a dynamic course with significant fluctuations of HBV-DNA and ALT impeding assessment of disease activity. New biomarkers of inflammatory versus noninflammatory stages of HBV infection are urgently needed. Cytokeratin 18 epitope M30 (M30 CK-18) is a sensitive marker of cell death. We aimed to investigate an association between serum M30 CK-18 and histological activity and phase of HBV infection. 150 Caucasian patients with HBV-infection were included in the study. Serum M30 CK-18 levels reflected phase of disease, being significantly higher in both HBeAg(+) and HBeAg(−) hepatitis B in comparison to HBsAg(+) carrier groups. The highest serum M30 CK-18 levels were observed in subjects with the most advanced stages of HBV. Moreover, its serum concentrations correlated with both inflammatory activity and fibrosis advancement (ANOVA P<0.001). Importantly, serum M30 CK-18 levels were able to discriminate patients with mild versus moderate-advanced fibrosis (AUC: 0.86) and mild versus active liver inflammation (AUC: 0.79). M30 CK-18 serum concentration has good sensitivity and specificity in discriminating mild versus moderate/severe fibrosis and inflammation even in patients with normal ALT activity. This study suggests M30 CK-18 as a potential noninvasive marker of disease activity and also a marker of phase of persistent HBV infection.

scholarly journals Spectrum of Hepatits B Infection Among Patients Attending Liver Unit in Nepalgunj Medical College – Kohalpur

2018 ◽  
Vol 16 (2) ◽  
pp. 2-5
Author(s):  
Dipendra Khadka ◽  
Sudhamshu KC ◽  
Niyanta Karki ◽  
Sandip Khadka ◽  
Kiran Regmi
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Tertiary Care ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Hepatitis B Infection ◽  
Chronic Hbv Infection ◽  
Medical College ◽  
Liver Unit ◽  
Chronic Hbv

Introduction: Hepatitis B infection is a global problem. Hepatitis B virus (HBV) infection related liver disease is also not an uncommon problem in our country too. Reports regarding pattern of chronic HBV infection are also lacking. The aim of the present study was to determine the spectrum of chronic HBV infection among patients attending the liver clinic in a tertiary care center. Method: A hospital based descriptive cross-sectional study was carried out in Liver unit of Nepalgunj Medical College, Kohalpur, from April 2018 to November 2018. All patients with HBsAg positive were further tested for HBeAg, HBeAb, HBV DNA quantitative and liver function test. Ultrasound examination was advised for any evidence of chronic liver disease. Staging was done according to viral serology, liver biochemistry and ultrasonography of liver Results: Total patients enrolled were 119. Majority of patents were in between 30-60 years (51.3%) with male predominance 59.7%. Most of patients were in the stage of HBeAg negative chronic infection 66.4% with normal transaminase and HBV DNA <2000 IU/ML. Majority of patients having unknown source of infection 90.8%. Incidental detection (67.2%) was common mode of detection. Conclusions: Majority of patients were in HBeAg negative chronic hepatitis B infection phase with normal transaminase and low HBV DNA not requiring treatment.

scholarly journals Liver Disease in Asymptomatic Carriers of Hepatitis B Antigen

1974 ◽  
Vol 66 (5) ◽  
pp. 1020-1028 ◽  
Author(s):  
Jerome B. Simon ◽  
Subhash K. Patel
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Asymptomatic Carriers ◽  
Hepatitis B Antigen

scholarly journals Fatal Hepatic Decompensation in a Patient with Hepatitis B Cirrhosis Following Famciclovir Withdrawal

2000 ◽  
Vol 14 (8) ◽  
pp. 725-727 ◽  
Author(s):  
Robert P Myers ◽  
Rabindra Chaudhary ◽  
Kevin Fonseca ◽  
Samuel S Lee
Keyword(s):  
Liver Disease ◽  
Hepatitis B ◽  
Dna Polymerase ◽  
Nucleoside Analogue ◽  
Hbv Dna ◽  
Hbv Infection ◽  
Polymerase Gene ◽  
Hepatic Inflammation ◽  
Hepatic Decompensation ◽  
B Virus

Hepatitis B virus (HBV) infection is a major cause of chronic liver disease worldwide. Famciclovir is a nucleoside analogue with potent antiviral activity that appears promising in the management of patients with HBV infection. No data exist regarding the safety of nucleoside analogue withdrawal in patients treated for HBV cirrhosis. The authors describe a 41-year-old man with compensated HBV cirrhosis who developed fatal hepatic decompensation due to a rebound in viral replication within six weeks of discontinuing famciclovir therapy. Although several mutations in the HBV DNA polymerase gene have been documented, none has been associated with famciclovir resistance or adverse clinical outcomes. Clinicians should consider the risk of inducing serious flares in hepatic inflammation as a result of abrupt nucleoside analogue withdrawal. Until further data are available regarding the safety of withdrawal of these agents, indefinite treatment may be required in patients with established cirrhosis.

scholarly journals Parameters Associated with Significant Liver Histological Changes in Patients with Chronic Hepatitis B

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Li Xiao ◽  
Jianchun Xian ◽  
Yang Li ◽  
Aiwen Geng ◽  
Xiuzhen Yang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Advanced Fibrosis ◽  
Histological Changes ◽  
Factors Associated ◽  
Liver Histopathology ◽  
Liver Biopsies ◽  
Chronic Hbv ◽  
Normal Alt

This study aimed to evaluate factors associated with significant liver histological changes. Liver biopsies from 157 CHB patients were retrospectively analyzed. Only ALB was significantly correlated with advanced liver necroinflammatory (P=0.001). Age, ALB, GLOB, AST, PLT, and PT were independent predictors of significant fibrosis (P=0.002, P<0.001, P=0.001, P=0.048, P<0.001, and P=0.001, resp.). AST, WBC, and HBV DNA were significantly correlated with advanced fibrosis in normal ALT patients (P<0.001, P=0.041, and P=0.012, resp.) and age, ALB, GLOB, PLT, and PT in patients with abnormal ALT (P=0.003, P<0.001, P=0.004, P<0.001, and P=0.002, resp.). Age, AST, GGT, PLT, and PT were significantly associated with advanced fibrosis in HBeAg+ patients (P=0.01, P=0.016, P=0.027, P=0.016, and P=0.009, resp.) and ALB, GLOB, WBC, PLT, and PT in HBeAg− patients (P<0.001, P=0.004, P=0.005, P<0.001, and P=0.035, resp.). PLT was an excellent predictor for cirrhosis (P<0.001 and AUROC=0.805). ALT was not predictive of advanced fibrosis for patients with HBeAg+ or HBeAg− (P=0.273 and P=0.599, resp.). PLT was an excellent predictor for cirrhosis in CHB patients. Liver histopathology can be recommended for chronic HBV carriers of older age, with normal ALT, lower PLT, and lower ALB.

scholarly journals 360. Advanced Liver Disease in HIV/Hepatitis B Coinfected Patients: Associated with Race, Age, and Comorbidities

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S189-S189
Author(s):  
Gabriella Go ◽  
Karen J Vigil ◽  
Paul Parisot ◽  
Trung Vu ◽  
Barbara Taylor ◽  
...  
Keyword(s):  
Risk Factors ◽  
Logistic Regression ◽  
Liver Disease ◽  
Hepatitis B ◽  
Hbv Dna ◽  
Cd4 Count ◽  
Advanced Liver Disease ◽  
Hiv Rna ◽  
Hbsag Loss ◽  
Hcv Coinfection

Abstract Background Hepatitis B virus (HBV) coinfection is common in people with HIV. Compared with HBV mono-infected individuals, those that are HIV/HBV coinfected show evidence of more rapid progression to advanced liver disease (ALD) and increased mortality rate. In this study, we identified characteristics in an HIV/HBV cohort associated with ALD. Methods We retrospectively examined an HIV/HBV coinfected cohort to determine the prevalence of ALD and its correlation with selected variables. Data were drawn from HIV and HBsAg+ patients at three HIV clinics in Houston, Dallas, and San Antonio, Texas. Those without chronic HBV were excluded. ALD was defined as cirrhosis, decompensation, and/or hepatocellular carcinoma, as determined by imaging. Variables included demographics, HIV risk factors, comorbidities, HBsAg loss, HepBeAg, CD4+ count, HBV DNA, and HIV RNA viral load. Bivariate analysis was performed using chi-square and student t-test as appropriate; a logistic regression model was used to identify independent associations among significant variables (STATA). Results Within those with HIV/HBV coinfection (n = 501), 89 (18%) met the criteria for ALD (92% male, 47% Black, 33% White, 16% Hispanic, 73% >40 years old). Amongst these (n = 89), significant differences were observed with race (P = 0.039), age (P = 0.001), patients identified as MSM/Bisexuals (P = 0.047), diabetes mellitus (DM) (P = 0.01) and hepatitis C virus (HCV) coinfection (P ≤ 0.001). Compared with Whites, Blacks are less likely to have ALD (95% CI 0.27, 0.79, P = 0.004), and those age 40–49 (95% CI 1.28, 10.92, P = 0.016) and >50 (95% CI 1.63, 15.54, P = 0.005) were more likely. The multivariate logistic regression analysis showed patients that are White race, age >50, have DM, and those with HCV coinfection had increased risk for ALD (Table 1). No differences were seen with gender, insurance, alcohol use, HBsAg loss, HepBeAg status or baseline CD4+ count, HBV DNA, HIV RNA, and AIDS. Conclusion Increased monitoring for the presence of ADL should be conducted in HIV/HBV coinfection. Particular attention and surveillance should be paid to those with the following risk factors: Whites, elder age (>50), and comorbidities of DM and HCV. These should be taken into consideration when approaching the development and treatment of ADL in HIV/HBV patients. Disclosures All authors: No reported disclosures.

Su1019 High Normal ALT and Borderline HBV DNA Were Predictors for Future Treatment Eligibility in Chronic Hepatitis B (CHB) Patients Who Initially Did Not Meet Criteria

2014 ◽  
Vol 146 (5) ◽  
pp. S-964
Author(s):  
Lindsay Uribe ◽  
Nghia Nguyen ◽  
Long H. Nguyen ◽  
Lily H. Kim ◽  
Huy N. Trinh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hbv Dna ◽  
Future Treatment ◽  
Normal Alt
Sign in / Sign up

Export Citation Format

Share Document